Harikrishnan Mohan

Dr. Harikrishnan Mohan

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Plant Physiology and Biochemistry
Verified
Journal Article
Closed access
GVGayatri Venkataraman
Gayatri Venkataraman
Sergey ShabalaSergey Shabala
Sergey Shabala
AVAnne-Aliénor Véry
Anne-Aliénor Véry
GHGopalasamudram Neelakantan Hariharan
Gopalasamudram Neelakantan Hariharan
SSSuji Somasundaram
Suji Somasundaram
Zhong-Hua ChenZhong-Hua Chen
Zhong-Hua Chen

10 February 2025 in Journal of Medical Virology
Verified
Journal Article
Closed access
RNRafiq Nabi
Rafiq Nabi
VCVladimir N. Chouljenko
Vladimir N. Chouljenko
FMFarhana Musarrat
Farhana Musarrat
MDMegan E. Davis
Megan E. Davis
HMHarikrishnan Mohan
Harikrishnan Mohan
KKKonstantin G Kousoulas
Konstantin G Kousoulas

19 July 2026 in Viruses
Verified
Journal Article
Open access
PDF file
Md Imran HossainMd Imran Hossain
Md Imran Hossain
MAMd Arifuzzaman
Md Arifuzzaman
MHMd Mehedi Hasan
Md Mehedi Hasan
SPSeung-Jong Park
Seung-Jong Park
LRLeila Rahimian
Leila Rahimian
KKKonstantin G Kousoulas
Konstantin G Kousoulas
The herpes simplex virus 1 (HSV-1) US3 is a multifunctional serine/threonine kinase that promotes HSV-1 replication and spread. But its role and the mechanisms by which US3 regulates actin cytoskeletal remodeling remain poorly defined. We combined flow cytometry, confocal microscopy, immunoprecipitation-mass spectrometry (IP-MS), protein complex mapping, and machine learning to characterize US3-mediated F-actin dynamics. Flow cytometry and confocal microscopy showed that wild-type HSV-1 induces significant F-actin remodeling, while the ΔUS3 mutant displays F-actin levels comparable to uninfected cells, identifying US3 as a key regulator. IP-MS identified 47 high-confidence US3 interactors enriched in conserved actin regulatory complexes, including Arp2/3 nucleation machinery, formin-associated assemblies, cofilin severing complexes, and Rho-family GTPase modules. Mapping interactors to the CORUM database revealed clustering within actin nucleation, polymerization, and severing complexes, indicating that US3 operates through organized cellular machines. Machine-learning classifiers trained on label-independent mass-spectrometry features were used to prioritize interactors resembling known actin regulators; under protein-group-aware cross-validation, logistic regression performed best (average precision 0.24; ROC-AUC 0.66), and the analysis was interpreted as prioritization rather than de novo discovery. Pharmacological inhibition of Arp2/3 and formin pathways significantly attenuated US3-dependent F-actin remodeling, supporting the functional involvement of these pathways. Together, these findings are consistent with an inferred hierarchical axis in which US3 modulates Rho GTPase signaling and cofilin activation to promote F-actin disassembly, coordinating cytoskeletal remodeling required for efficient viral egress and spread.

26 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KKKonstantin G Kousoulas
Konstantin G Kousoulas
ODOjasvi Dutta
Ojasvi Dutta
HMHarikrishnan Mohan
Harikrishnan Mohan
AFAgustin Fernandez
Agustin Fernandez
The term "vaccine" has been broadly and inconsistently applied to a range of products with widely divergent immunological outcomes, leading to the erosion of public trust and confusion among both medical professionals and the public. Historically, and by broad public understanding, a vaccine is expected to prevent infection, transmission, and disease through the induction of sterilizing, or true neutralizing immunity, specifically, the prevention of pathogen entry and replication in vivo. This ideal extends beyond the mere elicitation of neutralizing antibodies demonstrable in vitro. This paper proposes a three-tier classification system designed to differentiate products currently designated as "vaccines," specifically to address the distinction between those that meet the traditional, highest-expectation definition (Tier 1), therapeutic vaccines that primarily prevent disease (Tier 2), and immunomodulatory therapeutics that primarily reduce disease severity (Tier 3). By detailing the mechanism of action of each product and emphasizing the urgent need for this refined classification, our aim is to restore public confidence in vaccination programs, improve understanding of vaccine-induced immunity among healthcare professionals, and empower informed decision-making by the public. We argue that a clearer understanding of vaccine capabilities will ultimately lead to increased vaccine uptake for those vaccines that do prevent infection, transmission, and disease.

8 August 2025 in Hygiene
Verified
Journal Article
Open access
PDF file
KKKonstantin G Kousoulas
Konstantin G Kousoulas
ODOjasvi Dutta
Ojasvi Dutta
HMHarikrishnan Mohan
Harikrishnan Mohan
AFAgustin Fernandez
Agustin Fernandez
The term “vaccine” has been broadly and inconsistently applied to a range of products with widely divergent immunological outcomes, leading to the erosion of public trust and confusion among both medical professionals and the public. Historically, and by broad public understanding, a vaccine is expected to prevent infection, transmission, and disease through the induction of sterilizing, or true neutralizing immunity, specifically, the prevention of pathogen entry and replication in vivo. This ideal extends beyond the mere elicitation of neutralizing antibodies demonstrable in vitro. This paper proposes a three-tier classification system designed to differentiate products currently designated as “vaccines,” specifically to address the distinction between those that meet the traditional, highest-expectation definition (Tier 1), therapeutic vaccines that primarily prevent disease (Tier 2), and immunomodulatory therapeutics that primarily reduce disease severity (Tier 3). By detailing the mechanism of action of each product and emphasizing the urgent need for this refined classification, our aim is to restore public confidence in vaccination programs, improve understanding of vaccine-induced immunity among healthcare professionals, and empower informed decision-making by the public. We argue that a clearer understanding of vaccine capabilities will ultimately lead to increased vaccine uptake for those vaccines that do prevent infection, transmission, and disease.

18 September 2024
Verified
Preprint
Open access
RNRafiq Nabi
Rafiq Nabi
VCVladimir Chouljenko
Vladimir Chouljenko
FMFarhana Musarrat
Farhana Musarrat
MEMegan Davis E
Megan Davis E
HMHarikrishnan Mohan
Harikrishnan Mohan
GKGus Kousoulas
Gus Kousoulas
Not-yet-known not-yet-known not-yet-known unknown Oncolytic virotherapy (OVT) aims to disrupt the tumor microenvironment and provide a unique therapeutic approach against solid tumors. Herpes Simplex Virus Type-1 (HSV-1) has shown strong promise for treating various solid tumors and has been approved to treat melanoma and glioma in human patients. Previously, we reported the generation of an engineered HSV-1 vaccine strain VC2, which has shown exceptional promise as an oncolytic and immunotherapeutic virus. In the present work, we engineered VC2 to constitutively express the murine Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) gene inserted in place of HSV-1 Glycoprotein C (gC). We tested the efficacy of VC2-GMCSF for its ability to generate anti-tumor response in the 4T1 stage four metastatic breast cancer mouse model. GM-CSF expression enhanced VC2 viral replication and infectious virus production. Tumors formed after 7 days of engraftment in the mammary fat-pad of Balb/CJ mice were treated by injecting ~10 6 plaque forming units (PFU) once. Intra-tumor treatment did not appreciably reduce average primary tumor sizes. However, metastatic foci were significantly reduced in mice lungs treated with VC2-GMCSF compared to VC2 or mock treatment. VC2-GMCSF intratumoral treatment induced a stronger intratumor T cell infiltration but not an increased cytotoxic activity. A significant T cell infiltration was observed in the metastatic areas in VC2-GMCSF treated animals, which was associated with reduced pro-tumor marker PDL1 and VEGF gene expression. These results show that constitutive expression of GM-CSF enhanced the overall efficacy of VC2 for oncolytic virotherapy. VC2-GMCSF holds promise as an oncolytic and immunotherapeutic virotherapy for breast and other cancers.